BARCELONA, Spain--(BUSINESS WIRE)--Medical diagnostics company STAT-Diagnostica has closed a Series C financing round totaling 25 million Euros/28.5 million USD. The proceeds will be used to prepare for the 2017 European launch of its DiagCORE Near Patient Testing system. Led by new investor Gilde Healthcare, the financing round also drew participation from existing investors, including Kurma Partners; Ysios Capital; Idinvest Partners; Boehringer Ingelheim Venture Fund; Caixa Capital Risc; and Axis.
“STAT-Diagnostica’s DiagCORE system can become the best-in-class platform for decentralized molecular testing, the most attractive growth area in molecular diagnostics today,” said Arthur Franken, partner, Gilde Healthcare. “The company’s exceptional team has taken the product from idea to commercial implementation in just a few years, a tremendous achievement that stands to bring significant benefit to practitioners and patients.”
“We are very pleased to have strengthened our existing investor base with Gilde Healthcare,” said Jordi Carrera, CEO and co-founder of STAT-Diagnostica. “This transaction paves the way for us to become the leader in the decentralized syndromic-approach diagnostics space, the fastest growing segment of in-vitro diagnostics.”
DiagCORE is a fully integrated molecular and immunoassay diagnostics system that delivers lab-like performance in just one step, providing unrivaled usability for true walk-away diagnostics. DiagCORE performs all sample prep steps on board for a wide range of sample types (e.g., whole blood, swabs, BAL, stool, sputum) while offering up to 48-multiplex capabilities via real-time PCR. Time to results can be as low as 30 and up to 80 minutes, depending on the assay type. DiagCORE’s rapid performance is expected to improve clinical decision making and deliver better patient management and cost savings to the healthcare system.
STAT-Diagnostica plans to target a range of decentralized testing environments with DiagCORE, including critical care and emergency medicine units within hospitals. The system will also have CLIA-waivable features that will allow it to be used in clinics and physician offices.
Founded in 2010 in Barcelona, STAT-Diagnostica is focused on the development of Near Patient Testing solutions where fast and accurate diagnostic results are needed. Its DiagCORE in vitro diagnostic system is a versatile, easy-to-use platform that consolidates molecular and immunoassay techniques in a single device.